A decrease in plasma glucose levels is required for increased endogenous glucose production with a single administration of a sodium-glucose co-transporter-2 inhibitor tofogliflozin.
Nozomu YamasakiYoshifumi TamuraHideyoshi KagaMotonori SatoMai KiyaSatoshi KadowakiRuriko SuzukiYasuhiko FurukawaDaisuke SugimotoTakashi FunayamaYuki SomeyaSaori KakehiShuko NojiriHiroaki SatohRyuzo KawamoriHirotaka WatadaPublished in: Diabetes, obesity & metabolism (2021)
These results indicate that the decrease in PG levels induced by SGLT2 inhibitor administration is required for the increase in EGP and decrease in insulin secretion.